<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04698057</url>
  </required_header>
  <id_info>
    <org_study_id>ACACIA</org_study_id>
    <nct_id>NCT04698057</nct_id>
  </id_info>
  <brief_title>Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial.</brief_title>
  <acronym>ACACIA</acronym>
  <official_title>Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In low risk neutropenic fever in cancer, standard of care is the association of amoxicillin&#xD;
      clavulanate and ciprofloxacin. But in this population, the rate of fever related to infection&#xD;
      is very low, leading to a overtreatment of the patients. The aim of this study is to validate&#xD;
      a descalation of the antibiotherapy with safety concerns.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate</measure>
    <time_frame>7 days</time_frame>
    <description>The success rate is defined by the proportion of patients receiving the tested regimen:&#xD;
with resolution of fever ≤72h after the start of antibiotics (total duration of antibiotics expected : 5 days)&#xD;
AND without any modification of the antibiotic regimen (route, dosage, combination total duration of antibiotics expected : 5 days),&#xD;
AND without fever recurrence in 48h following the discontinuation of antibiotics (so end of the measure of the main outcome at day 7).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Amoxicillin clavulanate + ciprofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with amoxicillin-clavulanate 1g tib and ciprofloxacine 750mg bid for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin clavulanate + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with amoxicillin-clavulanate 1g tib for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The aim of the study is to validate the desescalation of the treatment to stop ciprofloxacin prescription that may not impact the outcome of the patients but add toxicity and antibiotics selection. Placebo will be administred in the experimental arm</description>
    <arm_group_label>Amoxicillin clavulanate + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin Clavulanate</intervention_name>
    <description>Will be administred to all patients</description>
    <arm_group_label>Amoxicillin clavulanate + Placebo</arm_group_label>
    <arm_group_label>Amoxicillin clavulanate + ciprofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Will be administred to patients in the standard of care arm</description>
    <arm_group_label>Amoxicillin clavulanate + ciprofloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ≥ 18 years old&#xD;
&#xD;
          -  Treated for a solid cancer or a hematological malignancy&#xD;
&#xD;
          -  Presented with low-risk* febrile neutropenia due to chemotherapy with an expected&#xD;
             duration of neutropenia ≤ 7 days&#xD;
&#xD;
          -  Neutropenia is defined by an absolute neutrophil count ≤ 500/mm3.&#xD;
&#xD;
          -  Fever is defined by temperature ≥ 38.3° or ≥ 38° twice during a 1-hour interval.&#xD;
&#xD;
          -  Signing informed consent *Low risk is defined by MASCC score ≥ 21&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to the active substances: amoxicillin-clavulanic, ciprofloxacin,&#xD;
             penicillins, to other quinolones or to one of the excipient&#xD;
&#xD;
          -  History of severe immediate hypersensitivity reaction to another beta-lactam&#xD;
&#xD;
          -  History of jaunditis/hepatic impairment related to amoxicillin/clavulanic&#xD;
&#xD;
          -  Concomitant administration of ciprofloxacin and tizanidine.&#xD;
&#xD;
          -  Clinical signs of focal infection including history of untreated dental abscess.&#xD;
&#xD;
          -  Signs of sepsis or organ failure.&#xD;
&#xD;
          -  Severe immune deficiency other than the current cancer, except controlled-HIV&#xD;
             infection&#xD;
&#xD;
          -  Gastrointestinal symptoms requiring intravenous treatment (mucositis, vomiting, severe&#xD;
             diarrhea...).&#xD;
&#xD;
          -  Known aminotransferase serum levels &gt; 5 x normal values.&#xD;
&#xD;
          -  Known renal insufficiency defined as creatinine clearance of &lt; 30 mL/min (MDRD).&#xD;
&#xD;
          -  Antibiotherapy within 24h before enrollment. Prophylactic use of amoxicillin is an&#xD;
             exclusion criterium whereas prophylactic use of trimethoprim-sulfamethoxazole&#xD;
             (cotrimoxazole) and penicillin G (Oracilline®) are not and will be considered in the&#xD;
             analysis.&#xD;
&#xD;
          -  History of infection or colonization due to bacteria resistant to experimental drugs&#xD;
             in the previous year&#xD;
&#xD;
          -  Can be enrolled in the study only once.&#xD;
&#xD;
          -  Patients not benefiting from a Social Security scheme or not benefiting from it&#xD;
             through a third party.&#xD;
&#xD;
          -  Persons benefiting from enhanced protection, namely minors, persons deprived of their&#xD;
             liberty by a judicial or administrative decision, persons staying in a health or&#xD;
             social institution, adults under legal protection, and finally patients in emergencies&#xD;
&#xD;
          -  Pregnant or breastfeeding women, women at age to procreate and not using effective&#xD;
             contraception (either hormonal / mechanical : oral, injection, subcutaneous,&#xD;
             implantable, intrauterine device, or surgical : tubal ligation, hysterectomy, total&#xD;
             ovariectomy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathieu Puyade, MD, PhD</last_name>
    <phone>+33 5 49 44 32 76</phone>
    <email>mathieu.puyade@chu-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Corinne Lorrain</last_name>
    <phone>+33 5 49 44 39 30</phone>
    <email>Corinne.LORRAIN@chu-poitiers.fr</email>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

